Human anti-IL-23 antibodies, compositions, methods and uses
A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
1. An isolated IL-23p19 antibody, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106.
2. An isolated IL-23p19 antibody, comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:116 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 106.
3. An isolated IL-23p19 antibody, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106 having up to three substitutions from residues 50-66 of the amino acid sequence of SEQ ID NO: 106.
4. An isolated IL-23p19 antibody, comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 116 and the heavy chain variable region of claim 3 .
5. An IL-23p19 antibody according to any of claims 1 - 4 , wherein said antibody binds IL-23p19 with at least one affinity selected from at least 10 −9 M, at least 10 −10 M, at least 10 −11 M, and at least 10 −12 M, at least 10 −13 M, at least 10 −14 M, and at least 10 −15 M, as determined by surface plasmon resonance or the Kinexa method.
6. An IL-23p19 antibody according to any of claims 1 - 4 , wherein said antibody substantially modulates an activity of the IL-23 polypeptide, the activity selected from the group consisting of binding to the IL-23 receptor (IL-23R), induction of STAT3 phosphorylation, and IL-17 production.
7. A composition comprising the isolated IL-23p19 antibody according to claim 6 and at least one pharmaceutically acceptable carrier or diluent.
8. The composition according to claim 7 , further comprising at least one compound or polypeptide selected from a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic drug, an otic drug or nasal drug, a topical drug, a nutritional drug, and a cytokine antagonist.
9. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-23p19 antibody according to any of claims 1 - 4 .
10. The article of manufacture of claim 9 , wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.
11. The composition according to claim 7 , wherein the antibody is conjugated to a detectable label or reporter.